These include downregulation of major histocompatibility complexes (MHC) preventing tumor antigen presentation, or recruitment of anti-inflammatory tumor associated macrophages and regulatory T cells, which collectively hinders CD8 T cell targeting and fitness10,11. The gene discussed is HLA-C; the disease is neoplasm.